Know Cancer

or
forgot password

Polycystic Ovary Syndrome - Targeting the Sympathetic Nervous System to Improve Outcomes


Phase 4
18 Years
45 Years
Not Enrolling
Female
Polycystic Ovary Syndrome

Thank you

Trial Information

Polycystic Ovary Syndrome - Targeting the Sympathetic Nervous System to Improve Outcomes


Inclusion Criteria:



- Overweight and class I obese pre-menopausal women

- Diagnosis of PCOS by Rotterdam criteria

Exclusion Criteria:

- Any current medication

- pregnancy or the desire to become pregnant

- BMI > 35

- a history of type I diabetes, secondary hypertension not due to PCOS

- cardiovascular, cerebrovascular, liver or thyroid disease

- severe mental illness.

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Outcome Measure:

Microneurography

Outcome Description:

Microneurography is a technique developed to measure the sympathetic activitiy directly from the peroneal nerve. Microneurography will be performed at baseline visit and at 3 months follow up visit.

Outcome Time Frame:

3 months

Safety Issue:

No

Principal Investigator

Gavin Lambert, Dr

Investigator Role:

Principal Investigator

Investigator Affiliation:

BakerIDI Heart and Diabetes Institute

Authority:

Australia: Therapeutic Goods Administration

Study ID:

Human Neuro -PCOS

NCT ID:

NCT01504321

Start Date:

March 2012

Completion Date:

March 2013

Related Keywords:

  • Polycystic Ovary Syndrome
  • Polycystic Ovary syndrome
  • PCOS
  • sympathetic nervous system
  • moxonidine
  • Polycystic Ovary Syndrome

Name

Location